Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
Seres Therapeutics, Inc. (MCRB)
Last seres therapeutics, inc. earnings: 11/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.serestherapeutics.com
Company Research
Source: GlobeNewswire
Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration Additional presentations underscore the role of live biotherapeutics in shaping outcomes in IBD and immunocompromised patients CAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced three presentations at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) global congress, taking place April 17-21 in Munich, Germany. A poster presentation by Seres highlighted biomarker and clinical pharmacology data from the Company’s Phase 1b study of SER-155 (NCT04995653), evaluating changes in gastrointestinal (GI) microbiome composition following administration in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Data showed that administration of SER-155 induced a significa
Show less
Read more
Impact Snapshot
Event Time:
MCRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCRB alerts
High impacting Seres Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MCRB
News
- Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026GlobeNewswire
- Seres Therapeutics to Present at CARB-X Investor DayGlobeNewswire
- Seres Therapeutics (MCRB) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $22.00 price target on the stock.MarketBeat
- Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesGlobeNewswire
- Microbiome Market Competitive Landscape Report 2026: Comprehensive Insights About 140+ Companies and 180+ Drugs [Yahoo! Finance]Yahoo! Finance
MCRB
Earnings
- 3/12/26 - Beat
MCRB
Analyst Actions
- 3/13/26 - Canaccord Genuity
MCRB
Sec Filings
- 3/17/26 - Form 144
- 3/16/26 - Form 8-K
- 3/12/26 - Form 10-K
- MCRB's page on the SEC website